Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D02MBN
|
|||
Former ID |
DNCL001620
|
|||
Drug Name |
SD-6010
|
|||
Indication | Osteoarthritis [ICD-11: FA00-FA05; ICD-9: 715] | Phase 3 | [1] | |
Company |
Pfizer New York, NY
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Nitric-oxide synthase inducible (NOS2) | Target Info | Inhibitor | [2] |
BioCyc | Citrulline-nitric oxide cycle | |||
KEGG Pathway | Arginine biosynthesis | |||
Arginine and proline metabolism | ||||
Metabolic pathways | ||||
Calcium signaling pathway | ||||
HIF-1 signaling pathway | ||||
Peroxisome | ||||
Salmonella infection | ||||
Pertussis | ||||
Leishmaniasis | ||||
Chagas disease (American trypanosomiasis) | ||||
Toxoplasmosis | ||||
Amoebiasis | ||||
Tuberculosis | ||||
Pathways in cancer | ||||
Small cell lung cancer | ||||
NetPath Pathway | IL1 Signaling Pathway | |||
IL2 Signaling Pathway | ||||
Pathway Interaction Database | IL12-mediated signaling events | |||
Alpha9 beta1 integrin signaling events | ||||
ATF-2 transcription factor network | ||||
IL23-mediated signaling events | ||||
Signaling mediated by p38-alpha and p38-beta | ||||
HIF-1-alpha transcription factor network | ||||
Reactome | ROS production in response to bacteria | |||
Nitric oxide stimulates guanylate cyclase | ||||
WikiPathways | Type II interferon signaling (IFNG) | |||
Spinal Cord Injury | ||||
AGE/RAGE pathway | ||||
Effects of Nitric Oxide |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01438918) X-Ray Study Investigating The Safety And Efficacy Of SD-6010 In Subjects With Osteoarthritis Of The Knee. U.S. National Institutes of Health. | |||
REF 2 | A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.